Identification of Combinatorial Drugs that Synergistically Kill both Eribulin-Sensitive and Eribulin-Insensitive Tumor Cells
Open Access
- 4 November 2015
- journal article
- Published by Peertechz Publications Private Limited in Global Journal of Cancer Therapy
- Vol. 1 (1), 009-017
- https://doi.org/10.17352/gjct.000004
Abstract
Global Journal of Cancer Therapy is an academic, open access and well-established journal which is keen to publishing high quality manuscripts focusing on cancer therapy. The peer reviewed journal which creates scientific platform is taking into an account on all the most recent and outstanding research articles, technical reports, regular book reviews, scientific data, letters, opinions, reviews, editorials, case reports and short communication in all major areas of Cancer therapy.Keywords
This publication has 30 references indexed in Scilit:
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Melanoma — An Unlikely Poster Child for Personalized Cancer TherapyThe New England Journal of Medicine, 2010
- Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic InstabilityBiochemistry, 2009
- Synergistic drug combinations tend to improve therapeutically relevant selectivityNature Biotechnology, 2009
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene, 2008
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Chemical combination effects predict connectivity in biological systemsMolecular Systems Biology, 2007
- Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trialBritish Journal of Cancer, 2006